Published in Pain and Central Nervous System Week, January 15th, 2007
The patent claims broadly cover antisense drugs with "chimeric" or "gapmer" structures, including Isis' proprietary second-generation structures and the compositions of numerous other antisense compounds. More specifically, the claims cover a class of antisense compounds, any of which is designed to have a sequence of phosphorothioate-linked nucleotides having two regions of chemically modified RNA flanking a region of DNA. This design, along...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.